CRBU — Caribou Biosciences Share Price
Last trade - 00:00- $379.32m
- $50.49m
- $34.48m
- 42
- 23
- 65
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.03 | ||
| Price to Tang. Book | 1.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.73% | ||
| Return on Equity | -30.5% | ||
| Operating Margin | -336.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.79 | 12.36 | 9.6 | 13.85 | 34.48 | 12.27 | 12.97 | 56.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.
Directors
- Rachel Haurwitz PRE (36)
- Jason O'byrne CFO (53)
- Cherry Thomas SVP
- Steven Kanner CSO (62)
- Ruhi Khan OTH
- Syed Rizvi OTH
- Barbara McClung SEC (66)
- Dara Richardson - Heron DRC
- Nancy Whiting DRC
- Ran Zheng DRC
- Scott Braunstein IND (57)
- Andrew Guggenhime IND (51)
- Natalie Sacks IND (56)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 28th, 2011
- Public Since
- July 23rd, 2021
- No. of Shareholders
- 40
- No. of Employees
- 158
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 90,314,501
- Address
- 2929 7TH STREET, STE 120, BERKELEY, 94710
- Web
- https://www.cariboubio.com/
- Phone
- +1 5109826030
- Auditors
- Deloitte & Touche LLP
Upcoming Events for CRBU
Similar to CRBU
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:04 UTC, shares in Caribou Biosciences are trading at $4.20. This share price information is delayed by 15 minutes.
Shares in Caribou Biosciences last closed at $4.20 and the price had moved by -13.4% over the past 365 days. In terms of relative price strength the Caribou Biosciences share price has underperformed the S&P500 Index by -30.06% over the past year.
The overall consensus recommendation for Caribou Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Caribou Biosciences does not currently pay a dividend.
Caribou Biosciences does not currently pay a dividend.
Caribou Biosciences does not currently pay a dividend.
To buy shares in Caribou Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $4.20, shares in Caribou Biosciences had a market capitalisation of $379.32m.
Here are the trading details for Caribou Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CRBU
Based on an overall assessment of its quality, value and momentum Caribou Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Caribou Biosciences is $20.00. That is 376.19% above the last closing price of $4.20.
Analysts covering Caribou Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.74 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Caribou Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -14.43%.
As of the last closing price of $4.20, shares in Caribou Biosciences were trading -26.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Caribou Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Caribou Biosciences' management team is headed by:
- Rachel Haurwitz - PRE
- Jason O'byrne - CFO
- Cherry Thomas - SVP
- Steven Kanner - CSO
- Ruhi Khan - OTH
- Syed Rizvi - OTH
- Barbara McClung - SEC
- Dara Richardson - Heron - DRC
- Nancy Whiting - DRC
- Ran Zheng - DRC
- Scott Braunstein - IND
- Andrew Guggenhime - IND
- Natalie Sacks - IND